These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 28407394)

  • 1. Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population.
    Onem K; Bayrak O; Demirtas A; Coskun B; Dincer M; Kocak I; Onur R;
    Neurourol Urodyn; 2018 Jan; 37(1):263-268. PubMed ID: 28407394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
    Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
    J Urol; 2017 Feb; 197(2S):S216-S223. PubMed ID: 28012773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.
    Hsiao SM; Lin HH; Kuo HC
    PLoS One; 2016; 11(1):e0147137. PubMed ID: 26824901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OnabotulinumtoxinA detrusor injection improves female sexual function in women with overactive bladder wet syndrome.
    Balzarro M; Rubilotta E; Braga A; Bassi S; Processali T; Artibani W; Serati M
    Eur J Obstet Gynecol Reprod Biol; 2018 Jun; 225():228-231. PubMed ID: 29753213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia.
    Chughtai B; Dunphy C; Lee R; Lee D; Sheth S; Marks L; Kaplan SA; Te AE
    Can J Urol; 2014 Apr; 21(2):7217-21. PubMed ID: 24775575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.
    Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
    J Urol; 2013 Jun; 189(6):2186-93. PubMed ID: 23246476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center.
    Jiang YH; Ong HL; Kuo HC
    Neurourol Urodyn; 2017 Jan; 36(1):142-147. PubMed ID: 26417884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
    Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
    Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison.
    Cruz F; Danchenko N; Fahrbach K; Freitag A; Tarpey J; Whalen J
    J Med Econ; 2023; 26(1):200-207. PubMed ID: 36647624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNAs as potential biomarkers to predict the risk of urinary retention following intradetrusor onabotulinumtoxin-A injection.
    Chermansky CJ; Kadow BT; Kashyap M; Tyagi P
    Neurourol Urodyn; 2018 Jan; 37(1):99-105. PubMed ID: 28493606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity.
    Kanagarajah P; Ayyathurai R; Caruso DJ; Gomez C; Gousse AE
    Int Urol Nephrol; 2012 Feb; 44(1):91-7. PubMed ID: 21643644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study).
    Tincello DG; Kenyon S; Abrams KR; Mayne C; Toozs-Hobson P; Taylor D; Slack M
    Eur Urol; 2012 Sep; 62(3):507-14. PubMed ID: 22236796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study.
    Nitti VW; Ginsberg D; Sievert KD; Sussman D; Radomski S; Sand P; De Ridder D; Jenkins B; Magyar A; Chapple C;
    J Urol; 2016 Sep; 196(3):791-800. PubMed ID: 27038769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder.
    Jiang YH; Kuo HC
    Neurourol Urodyn; 2017 Feb; 36(2):338-343. PubMed ID: 26575613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of an alternative onabotulinumtoxinA injection paradigm for refractory overactive bladder.
    MacDiarmid S; Glazier DB; McCrery RJ; Kennelly MJ; Nelson M; Ifantides KB; McCammon KA
    Neurourol Urodyn; 2024 Jan; 43(1):31-43. PubMed ID: 37746881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can botox improve night-time overactive bladder symptoms in women?
    Miotla P; Cartwright R; Futyma K; Bogusiewicz M; Skorupska K; Winkler I; Rechberger T
    Neurourol Urodyn; 2017 Mar; 36(3):648-652. PubMed ID: 26915654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early and Consistent Improvements in Urinary Symptoms and Quality of Life With OnabotulinumtoxinA in Patients With Overactive Bladder and Urinary Incontinence: Results From a Randomized, Placebo-controlled, Phase IV Clinical Trial.
    McCammon K; Gousse A; Kohan A; Glazier D; Gruenenfelder J; Bai Z; Patel A; Hale D
    Female Pelvic Med Reconstr Surg; 2021 Jul; 27(7):450-456. PubMed ID: 32665528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis--Different Mechanisms of Action of Botox on Bladder Dysfunction?
    Kuo YC; Kuo HC
    Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26999201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.